<div><p>Background</p><p>HIV-1 infects the host cell by interacting with the primary receptor CD4 and a coreceptor CCR5 or CXCR4. Maraviroc, a CCR5 antagonist binds to CCR5 receptor. Thus, it is important to identify the coreceptor used by the HIV strains dominating in the patient. In past, a number of experimental assays and <i>in-silico</i> techniques have been developed for predicting the coreceptor tropism. The prediction accuracy of these methods is excellent when predicting CCR5(R5) tropic sequences but is relatively poor for CXCR4(X4) tropic sequences. Therefore, any new method for accurate determination of coreceptor usage would be of paramount importance to the successful management of HIV-infected individuals.</p><p>Results</p><p>...
The clinical application of CCR5 antagonists involves first determining the coreceptor usage by the ...
The V3 loop of human immunodeficiency virus type 1 (HIV-1) is critical for coreceptor binding and i...
\sectionMotivation:} Due to the high mutation rate of HIV, drug resistant variants emerge frequently...
techniques have been developed for predicting the coreceptor tropism. The prediction accuracy of th...
Maraviroc (MVC) is the first licensed antiretroviral drug from the class of coreceptor antagonists. ...
<div><p>HIV-1 entry into host cells is mediated by interactions between the V3-loop of viral glycopr...
HIV-1 cell entry commonly uses, in addition to CD4, one of the chemokine receptors CCR5 or CXCR4 as ...
<div><p>The relationship of HIV tropism with disease progression and the recent development of CCR5-...
HIV-1 cell entry commonly uses, in addition to CD4, one of the chemokine receptors CCR5 or CXCR4 as ...
It remains unknown whether the C-C motif chemokine receptor type 5 (CCR5) coreceptor is still the pr...
HIV infects target cells by binding of its envelope gp120 protein to CD4 and a coreceptor on the cel...
Early in infection, human immunodeficiency virus type 1 (HIV-1) generally uses the CCR5 chemokine re...
BACKGROUND: The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Alth...
HIV-1 cell entry commonly uses, in addition to CD4, one of the chemokine receptors CCR5 or CXCR4 as...
Background. Human immunodeficiency virus type 1 (HIV-1) uses the CD4 receptor and a coreceptor to ga...
The clinical application of CCR5 antagonists involves first determining the coreceptor usage by the ...
The V3 loop of human immunodeficiency virus type 1 (HIV-1) is critical for coreceptor binding and i...
\sectionMotivation:} Due to the high mutation rate of HIV, drug resistant variants emerge frequently...
techniques have been developed for predicting the coreceptor tropism. The prediction accuracy of th...
Maraviroc (MVC) is the first licensed antiretroviral drug from the class of coreceptor antagonists. ...
<div><p>HIV-1 entry into host cells is mediated by interactions between the V3-loop of viral glycopr...
HIV-1 cell entry commonly uses, in addition to CD4, one of the chemokine receptors CCR5 or CXCR4 as ...
<div><p>The relationship of HIV tropism with disease progression and the recent development of CCR5-...
HIV-1 cell entry commonly uses, in addition to CD4, one of the chemokine receptors CCR5 or CXCR4 as ...
It remains unknown whether the C-C motif chemokine receptor type 5 (CCR5) coreceptor is still the pr...
HIV infects target cells by binding of its envelope gp120 protein to CD4 and a coreceptor on the cel...
Early in infection, human immunodeficiency virus type 1 (HIV-1) generally uses the CCR5 chemokine re...
BACKGROUND: The majority of HIV-1 subjects worldwide are infected with HIV-1 subtype C (C-HIV). Alth...
HIV-1 cell entry commonly uses, in addition to CD4, one of the chemokine receptors CCR5 or CXCR4 as...
Background. Human immunodeficiency virus type 1 (HIV-1) uses the CD4 receptor and a coreceptor to ga...
The clinical application of CCR5 antagonists involves first determining the coreceptor usage by the ...
The V3 loop of human immunodeficiency virus type 1 (HIV-1) is critical for coreceptor binding and i...
\sectionMotivation:} Due to the high mutation rate of HIV, drug resistant variants emerge frequently...